Recent advances in immunotherapy research have revealed crucial roles for new immune cells in combating cancer, leading to ...

Prostate cancer and other cancers characterized by “cold” tumors could become more responsive to checkpoint blockade if UBA1 is inhibited.

Donisi, C, Pretta, A, Pusceddu, V, Ziranu, P, Lai, E, Puzzoni, M, Mariani, S, Massa, E, Madeddu, C and Scartozzi, M (2024) ...

A study from the University of Michigan Health Rogel Cancer Center may have—at last—cracked the cold case of immunotherapy ...

A study uncovers how cancer cells adapt to low-glucose environments, resisting chemotherapy by conserving uridine nucleotides ...

Study uses spatial transcriptomics to map intratumoral heterogeneity and microenvironmental dynamics in triple-negative ...

A recent study reveals that immunosuppression, or reduced immune response, in prostate cancer is associated with a ...

A study from the University of Michigan Health Rogel Cancer Center may have, at last, cracked the cold case of immunotherapy resistance.The research ...

Tumor cells transform fibroblasts into cancer-associated fibroblasts, which have an important immunosuppressive activity on which growth, invasion, and metastasis depend. These activated fibroblasts ...

University of Michigan researchers identified UBA1 as a key player in immunotherapy resistance. Inhibiting UBA1 boosts T-cell ...

TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies ...

A recent study by a team of researchers at Vanderbilt University found that response to radiation therapy for triple negative ...